FAGR Fagron SA

Disclosure of notification received from Alychlo

Disclosure of notification received from Alychlo

Regulated information

Nazareth (Belgium)/Rotterdam (The Netherlands), 18 July 2025 – 6 PM CET

Disclosure of notification received from Alychlo

Fagron received a notification based on the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies from Alychlo NV.

Notification by Alychlo NV

  • On 14 July 2025, Fagron received a notification that the shareholding of Alychlo NV, crossed the disclosure threshold of 3% downwards as the result of the disposal of voting securities or voting rights on 25 July 2024.
  • The notification is made by a ‘parent undertaking or a controlling person’.
  • On 25 July 2024 Alychlo NV held a total of 2,139,886 voting rights. In addition, Marc Coucke held 7,047 voting rights.
  • Based on the denominator of 73,228,904 (total number of voting rights) at that time, Alychlo NV and Marc Coucke together held 2.93% of the total number of voting rights on 25 July 2024.
  • The notification of Alychlo NV can be viewed via this .



Further information

Ignacio Artola

Global Investor Relations Leader

About Fagron

Fagron is a leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics, and patients in more than 30 countries around the world.

Belgian company Fagron NV has its registered office in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol ‘FAGR’. Fagron’s operational activities are managed by the Dutch company Fagron BV, which is headquartered in Rotterdam.

Important information regarding forward-looking statements

Certain statements in this press release may be deemed to be forward-looking. Such forward-looking statements are based on current expectations and are influenced by various risks and uncertainties. Consequently, Fagron cannot provide any guarantee that such forward-looking statements will, in fact, materialize and cannot accept any obligation to update or revise any forward-looking statement as a result of new information, future events or for any other reason.

In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.

Attachment



EN
18/07/2025

Underlying

FAGRFagron SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Fagron SA

 PRESS RELEASE
Free
FAGR FAGRON SA

Fagron publishes its Annual Report 2025

Fagron publishes its Annual Report 2025 Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 6 March 2026 7AM CET Fagron publishes its Annual Report 2025 Fagron, the leading global player in pharmaceutical compounding, today publishes its Annual Report 2025, further to its earlier announcement of Fagron's annual financial results for the financial year 2025 on February 12, 2026. The Annual Report is available on Fagron's in both Dutch (official version, including the ESEF-tagged version) and English. It comprises the annual financial report relating to the consolidated f...

March 6, 2026 1 EN
 PRESS RELEASE
Free
FAGR FAGRON SA

Fagron publiceert haar Jaarverslag 2025

Fagron publiceert haar Jaarverslag 2025 Gereglementeerde informatieNazareth (België)/Rotterdam (Nederland), 6 maart 2026 – 7:00 CET Fagron publiceert haar Jaarverslag 2025 Fagron, de toonaangevende wereldwijde speler in farmaceutische bereidingen, publiceert vandaag haar Jaarverslag 2025, volgend op de eerdere bekendmaking van Fagron's jaarlijkse financiële resultaten over het boekjaar 2025 op 12 februari 2026.  Het Jaarverslag is beschikbaar op de van Fagron in zowel het Nederlands (officiële versie, inclusief ESEF-getagde versie) als in het Engels. Het Jaarverslag omvat het financieel...

March 6, 2026 1 EN
 PRESS RELEASE
Free
FAGR FAGRON SA

Fagron completes acquisition of Vepakum

Fagron completes acquisition of Vepakum Regulated information – inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 3 March 2026 – 7:00AM Fagron completes acquisition of Vepakum Fagron, the leading global player in pharmaceutical compounding, announces the successful completion of its acquisition of Vepakum in Latin America. The transaction, announced in December 2025, was finalized following regulatory clearance from CADE in early February 2026. Vepakum operates two facilities in São Paulo, Brazil, and specializes in high-quality pharmaceutical packaging solutions. The ac...

March 3, 2026 1 EN
 PRESS RELEASE
Free
FAGR FAGRON SA

Fagron voltooit overname van Vepakum

Fagron voltooit overname van Vepakum Gereglementeerde informatie - voorwetenschapNazareth (België)/Rotterdam (Nederland), 3 maart 2026 – 7:00 Fagron voltooit overname van Vepakum Fagron, de toonaangevende wereldwijde speler in farmaceutische bereidingen, maakt bekend dat de overname van Vepakum in Latijns-Amerika succesvol is afgerond. De transactie, die in december 2025 werd aangekondigd, kon worden voltooid nadat CADE, de Braziliaanse mededingingsautoriteit, in februari 2026 goedkeuring verleende. Vepakum beschikt over twee productiefaciliteiten in São Paulo, Brazilië, en is gespecial...

March 3, 2026 1 EN
 PRESS RELEASE
Free
FAGR FAGRON SA

Disclosure of a transparency notification from AOC Pharma S.à r.l.

Disclosure of a transparency notification from AOC Pharma S.à r.l. Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 27 02 2026 – 6PM CET Disclosure of a transparency notification from AOC Pharma S.à r.l. Pursuant to the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in listed companies, Fagron received a transparency notification from AOC Pharma S.à r.l., dated 24 February 2026. Notification from AOC Pharma S.à r.l. On 24 February 2026, Fagron received a transparency notification from AOC Pharma S.à r.l., informing the Company that its sharehold...

February 27, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch